Study #2020-1238
A Multicenter, Open-Label Phase 1 Study Evaluating the Safety and Tolerability of HMPL-306 in Subjects with Locally Advanced or Metastatic Solid Tumors with IDH Mutations
MD Anderson Study Status
Not Accepting
Treatment Agent
HMPL-306
Description
An open label single-arm clinical trial to evaluate the safety, tolerability, PK, PD, and preliminary efficacy of HMPL-306 in advanced or metastatic solid tumors with IDH mutation.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Isocitrate Dehydrogenase Gene Mutation
Study phase:
Phase I
Physician name:
Jordi Rodon Ahnert
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-888-430-0627
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.